How Multiple Generic Drug Makers Drive Down Prices

Generic drug prices don’t drop because a company feels generous. They fall because someone else is selling the same pill for less-and then another, and another. When five, ten, or even twenty companies make the exact same medication, the price doesn’t just dip. It plummets. This isn’t theory. It’s math. And it’s saving millions of people thousands of dollars every year.

Take metformin, the most common diabetes drug in the U.S. In 2024, you could buy a 90-day supply for under $10 at many pharmacies. Why? Because at least eight different manufacturers make it. No single company controls the market. If one tries to raise prices, another steps in with a cheaper version. The result? A drug that once cost over $200 a month now costs less than a cup of coffee. That’s the power of competition.

How Many Competitors It Takes to Slash Prices

It’s not just about having a generic version. It’s about how many make it. A 2021 study from the University of Southern California tracked 50 brand-name drugs after their patents expired. The numbers tell the story:

• One generic manufacturer? Price drops just 17%.
• Two manufacturers? Down 39.5%.
• Three manufacturers? Down 52.5%.
• Four or more? Prices fall by over 70%.

That’s not a coincidence. Each new entrant forces everyone else to lower prices just to stay in the game. The biggest drops happen between the first and third competitors. After that, prices keep falling-but more slowly. Still, when ten companies make the same drug, prices often drop to 70-80% below what the brand-name version charged.

Compare that to a drug with only one or two generic makers. Those prices barely move. In some cases, they even rise. Why? Because there’s no pressure to compete. A 2017 study found that over half of all generic drugs in the U.S. have at most two manufacturers. That’s not competition. That’s a cozy oligopoly.

Why Some Drugs Stay Expensive

Not all generics work the same way. Oral pills-like antibiotics, blood pressure meds, or antidepressants-are easy to copy. The chemistry is simple. The manufacturing is straightforward. That’s why drugs like amoxicillin, lisinopril, or sertraline have dozens of makers and cost pennies.

But injectables, infusions, and complex biologics? Those are different. They’re harder to replicate. Fewer companies can make them. Even when biosimilars (the generic version of biologics) enter the market, they rarely drive prices down like simple generics do. One study found that if biosimilars were treated like regular generics under Medicare, spending on those drugs would’ve dropped nearly 27% between 2015 and 2019. But they weren’t. So prices stayed high.

And then there’s the supply chain. A drug might have five manufacturers, but if three of them are owned by the same parent company, it’s still effectively one player. That’s why mergers between small generic makers are so dangerous. Between 2014 and 2016, nearly 100 of these companies were bought up. The result? Fewer competitors. Higher prices. And patients caught in the middle.

What Happens When Competition Disappears

When a drug has only one or two makers, things get risky. If one company stops production-because of a factory issue, regulatory problem, or just because it’s not profitable anymore-the other one can raise prices overnight. No one else is left to step in.

Patients have reported price spikes of 300% to 500% for drugs like levetiracetam (used for epilepsy) or phenytoin (for seizures) after manufacturers left the market. One Reddit user in 2023 described paying $800 for a 30-day supply of a drug that used to cost $40. That’s not a pricing mistake. That’s market failure.

And it’s not just about cost. When manufacturers cut corners to stay profitable, quality suffers. Indiana University researchers found that price pressure in the generic market can lead to shortages-and worse, safety risks. A single plant failure can mean no drug at all for thousands of patients.

The Hidden Role of Pharmacy Benefit Managers

You might think PBMs (Pharmacy Benefit Managers) help lower prices. But their role is complicated. They negotiate bulk deals with drugmakers and pharmacies. In theory, that should cut costs. In practice, they often favor manufacturers that offer the biggest rebates-not the lowest prices.

That means a slightly more expensive drug might get priority on insurance formularies because it gives the PBM a bigger cut. The patient still pays the same out-of-pocket, but the real savings get buried in corporate deals. The FDA and FTC have both flagged this as a problem. Without transparency, it’s hard to know if you’re getting the cheapest option-or just the one that pays the middleman the most.

How to Use Competition to Save Money

You don’t need a degree in economics to use this system to your advantage. Here’s how:

1. Check the generic name. Your doctor might prescribe a brand name, but ask if a generic is available. Almost always, it is.
2. Use price comparison tools. GoodRx, SingleCare, and even your pharmacy’s website show prices across local pharmacies. The same drug can cost $5 at one store and $40 at another.
3. Ask about therapeutic equivalence. The FDA’s Orange Book lists which generics are interchangeable with the brand. Look for an “AB” rating. That means it’s identical in effectiveness.
4. Don’t assume your pharmacy’s choice is cheapest. Pharmacists can substitute generics, but sometimes they pick one based on inventory-not price. Ask them to check.
5. Buy in bulk. Many generics are cheaper at 90-day supplies. Especially for chronic conditions like diabetes or high blood pressure.

For example, a 90-day supply of generic atorvastatin (Lipitor) might cost $12 at Walmart, $28 at CVS, and $18 at Target. A two-minute search saves you $16 a month. That’s $192 a year. On a fixed income, that matters.

What’s Changing Now

The FDA’s Drug Competition Action Plan, launched in 2017, is trying to fix the broken parts of this system. It’s speeding up approvals for generics and cracking down on tactics brand-name companies use to delay competition-like paying generic makers to stay out of the market.

The CREATES Act of 2019 made it illegal for brand companies to block access to samples needed for generic testing. That’s a big win. But enforcement is still weak. And mergers keep slipping through federal review.

The good news? In 2022 alone, 742 new generic drugs were approved by the FDA. They’re projected to save the U.S. healthcare system $14.5 billion this year. That’s real money. Real relief.

The bad news? The trend is still toward fewer competitors. Small manufacturers are being swallowed by bigger ones. And the system isn’t designed to stop it.

What’s clear? Competition works. When multiple companies make the same drug, prices fall. When only one or two do, they rise. Patients don’t need more regulation. They need more competitors.

Next time you fill a prescription, ask: How many other companies make this? If the answer is fewer than three, you might be paying more than you need to. And that’s not just your problem. It’s a system failure.